Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $56.34, for a total transaction of $563,400.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $38,127,756.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Helen Torley also recently made the following trade(s):

• On Tuesday, September 10th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00.
• On Thursday, September 12th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $59.20, for a total value of $592,000.00.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $56.97 on Friday. The company has a market capitalization of $7.25 billion, a price-to-earnings ratio of 23.54, a price-to-earnings-growth ratio of 0.56 and a beta of 1.28. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $65.53. The company’s 50-day moving average is $58.67 and its 200 day moving average is $49.68.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.68 earnings per share. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. The Goldman Sachs Group raised their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Benchmark reissued a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday, September 13th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HALO. Rise Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $25,000. Whittier Trust Co. bought a new stake in shares of Halozyme Therapeutics in the first quarter worth $27,000. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the second quarter valued at about $33,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $49,000. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.